论文部分内容阅读
索拉菲尼是一种多激酶抑制剂,用于治疗晚期肾细胞癌及其他实体肿瘤。索拉菲尼常见不良反应之一为手足皮肤反应(HFSR),发生率为33.8%,临床表现为手足麻木感、麻刺感、红斑、皮肤发疱、发干、皲裂、脱屑。索拉菲尼致HFSR的发病机制尚不清楚,可能与抑制VEGF、PDGF、c-kit、RET及FLT3有关。HFSR的防治包括根据手足皮肤反应程度调整剂量及对症治疗。
Sorafenib is a multikinase inhibitor used to treat advanced renal cell carcinoma and other solid tumors. One of the common side effects of sorafenib is hand-foot skin reaction (HFSR), with an incidence rate of 33.8%. Clinical manifestations include numbness in hands and feet, tingling, erythema, skin blisters, dry hair, chapped and desquamation. The pathogenesis of sorafenib-induced HFSR is unclear, which may be related to the inhibition of VEGF, PDGF, c-kit, RET and FLT3. Prevention and treatment of HFSR includes adjusting the dose and symptomatic treatment according to the degree of hand-foot skin reaction.